Should I buy or sell Protagonist Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTGX shares. View PTGX analyst ratings or view top-rated stocks .

What is Protagonist Therapeutics' stock price target for 2024?

4 analysts have issued twelve-month price targets for Protagonist Therapeutics' shares. Their PTGX share price targets range from $32.00 to $38.00. On average, they expect the company's share price to reach $36.00 in the next year. This suggests a possible upside of 40.8% from the stock's current price. View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts .

How have PTGX shares performed in 2024?

Protagonist Therapeutics' stock was trading at $22.93 at the start of the year. Since then, PTGX stock has increased by 11.5% and is now trading at $25.57. View the best growth stocks for 2024 here .

When is Protagonist Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our PTGX earnings forecast .

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) posted its earnings results on Tuesday, February, 27th. The company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.05 by $0.39. The business earned $60 million during the quarter, compared to analyst estimates of $60 million.

What ETFs hold Protagonist Therapeutics' stock?

ETFs with the largest weight of Protagonist Therapeutics (NASDAQ:PTGX) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) . ALPS Medical Breakthroughs ETF (SBIO) .

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV) , Viking Therapeutics (VKTX) , ImmunoGen (IMGN) , SCYNEXIS (SCYX) , Energy Transfer (ET) , Strongbridge Biopharma (SBBP) , Verastem (VSTM) , Dynavax Technologies (DVAX) , Novavax (NVAX) and Sorrento Therapeutics (SRNE) .

When did Protagonist Therapeutics IPO?

Protagonist Therapeutics (PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.06%) and Los Angeles Capital Management LLC (0.05%). Insiders that own company stock include Asif Ali, David Y Liu , Dinesh V Ph D Patel , Suneel Gupta and William D Waddill. View institutional ownership trends .

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PTGX

Protagonist Therapeutics (PTGX) Stock Price, News & Analysis

→ Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad)

Free PTGX Stock Alerts

$25.57

-0.54 (-2.07%)

(As of 04/17/2024 ET)

Compare

Today's Range: $25.35
▼
$26.39
50-Day Range: $25.57
▼
$32.15
52-Week Range: $13.72
▼
$33.34

Volume: 517,565 shs
Average Volume: 718,478 shs
Market Capitalization: $1.49 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $36.00

Get Protagonist Therapeutics alerts:

Protagonist Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 40.8% Upside
$36.00 Price Target
Short Interest: Bearish
5.90% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$2.52 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From $1.18 to ($0.97) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.89 out of 5 stars

Medical Sector

635th out of 913 stocks

Pharmaceutical Preparations Industry

275th out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
Protagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Protagonist Therapeutics has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.90% of the outstanding shares of Protagonist Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Protagonist Therapeutics has a short interest ratio ("days to cover") of 4.6.
Change versus previous month
Short interest in Protagonist Therapeutics has recently increased by 0.58%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Protagonist Therapeutics does not currently pay a dividend.
Dividend Growth
Protagonist Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PTGX.

0.6

News and Social Media Coverage

Search Interest
Only 7 people have searched for PTGX on MarketBeat in the last 30 days. This is a decrease of -61% compared to the previous 30 days.
MarketBeat Follows
4 people have added Protagonist Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,522,342.00 in company stock.
Percentage Held by Insiders
Only 5.00% of the stock of Protagonist Therapeutics is held by insiders.
Percentage Held by Institutions
98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Protagonist Therapeutics are expected to decrease in the coming year, from $1.18 to ($0.97) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Protagonist Therapeutics is -17.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Protagonist Therapeutics is -17.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Protagonist Therapeutics has a P/B Ratio of 4.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

Click here to see the details.

About Protagonist Therapeutics Stock (NASDAQ:PTGX)

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

PTGX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PTGX Stock News Headlines

April 3, 2024 | insidertrades.com

Insider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells 25,000 Shares of Stock

April 3, 2024 | finance.yahoo.com

Protagonist Therapeutics Inc CEO Sells 25,000 Shares

April 17, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

April 1, 2024 | finance.yahoo.com

Shareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135%

March 27, 2024 | markets.businessinsider.com

Protagonist Therapeutics Earns ‘Buy’ Rating on Strong Clinical Progress and Strategic Partnerships

March 18, 2024 | finanznachrichten.de

Protagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda

March 15, 2024 | finance.yahoo.com

PTGX Apr 2024 15.000 call

March 15, 2024 | finance.yahoo.com

PTGX Apr 2024 30.000 put

April 17, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

March 12, 2024 | bizjournals.com

The People's Market owner snaps up former Protagonist space in heart of NoDa for bar

March 12, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Protagonist Therapeutics on Strong Phase 2b Results and Strategic Phase 3 Dosing of JNJ-2113

March 11, 2024 | markets.businessinsider.com

Strong Buy Rating for Protagonist Therapeutics on JNJ-2113’s Promising Psoriasis Treatment Efficacy and Financial Outlook

March 3, 2024 | finance.yahoo.com

This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year

March 2, 2024 | finance.yahoo.com

Earnings Update: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Just Reported And Analysts Are Boosting Their Estimates

March 1, 2024 | finance.yahoo.com

Protagonist Therapeutics Full Year 2023 Earnings: Beats Expectations

February 29, 2024 | finance.yahoo.com

We're Not Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn

February 28, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Protagonist Therapeutics on Strong Pipeline and Strategic Partnerships

February 28, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Gritstone Oncology (GRTS), Protagonist Therapeutics (PTGX)

February 25, 2024 | seekingalpha.com

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

February 21, 2024 | finance.yahoo.com

New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera

February 20, 2024 | finance.yahoo.com

Protagonist Therapeutics Reports Granting of Inducement Awards

February 17, 2024 | finance.yahoo.com

PTGX Mar 2024 25.000 call

February 15, 2024 | finance.yahoo.com

Steven Cohen Adjusts Position in Protagonist Therapeutics Inc

February 8, 2024 | msn.com

Protagonist Pictures Ups Janina Vilsmaier, Mounia Wissinger, Strengthens Sales and Marketing Divisions

February 8, 2024 | msn.com

Protagonist Pictures Promotes Janina Vilsmaier & Mounia Wissinger; Bolsters Sales & Marketing Teams Ahead Of EFM

February 7, 2024 | finance.yahoo.com

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

February 2, 2024 | markets.businessinsider.com

Buy Rating on Protagonist Therapeutics: Strategic Takeda Partnership and Rusfertide’s Market Potential

See More Headlines

Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PTGX
CUSIP: N/A
CIK: 1377121
Web: www.protagonist-inc.com
Phone: (510) 474-0170
Fax: N/A
Employees: 112
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $36.00
High Stock Price Target: $38.00
Low Stock Price Target: $32.00
Potential Upside/Downside: +40.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.49)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 21.67
P/E Growth: N/A
Net Income: $-78,960,000.00
Net Margins: N/A
Pretax Margin: -131.59%
Return on Equity: -27.49%
Return on Assets: -25.30%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.71
Quick Ratio: 16.71

Sales & Book Value

Annual Sales: $60 million
Price / Sales: 24.84
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.84 per share
Price / Book: 4.38

Miscellaneous

Outstanding Shares: 58,280,000
Free Float: 55,361,000
Market Cap: $1.49 billion
Optionable: Optionable
Beta: 2.01

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Dr. Dinesh V. Patel Ph.D. (Age 67)
CEO, President, Secretary & Director
Comp: $883.46k
Dr. Suneel K. Gupta Ph.D. (Age 65)
Chief Development Officer
Comp: $640.89k
Dr. Mark Smythe Ph.D. (Age 59)
Founder & VP Technology
Mr. Asif Ali (Age 50)
Executive VP & Chief Financial Officer
Mr. Mohammad Masjedizadeh Ph.D.
Executive VP & Chief Technical Officer
Mr. Matthew M. Gosling (Age 53)
Executive VP & General Counsel
Ms. Carena Spivey
Head of HR & Senior VP of Human Resources
Dr. Ashok Bhandari Ph.D. (Age 60)
Executive VP & Chief Drug Discovery and Preclinical Development Officer
Mr. Carter J. King (Age 53)
Executive Vice President of Business Development
Ms. Abha Bommireddi
Executive Vice President of Portfolio & Program Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PTGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Protagonist Therapeutics stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTGX shares.
View PTGX analyst ratings or view top-rated stocks.
What is Protagonist Therapeutics' stock price target for 2024?: 4 analysts have issued twelve-month price targets for Protagonist Therapeutics' shares. Their PTGX share price targets range from $32.00 to $38.00. On average, they expect the company's share price to reach $36.00 in the next year. This suggests a possible upside of 40.8% from the stock's current price.
View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts.
How have PTGX shares performed in 2024?: Protagonist Therapeutics' stock was trading at $22.93 at the start of the year. Since then, PTGX stock has increased by 11.5% and is now trading at $25.57.
View the best growth stocks for 2024 here.
When is Protagonist Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PTGX earnings forecast.
How were Protagonist Therapeutics' earnings last quarter?: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) posted its earnings results on Tuesday, February, 27th. The company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.05 by $0.39. The business earned $60 million during the quarter, compared to analyst estimates of $60 million.
What ETFs hold Protagonist Therapeutics' stock?: ETFs with the largest weight of Protagonist Therapeutics (NASDAQ:PTGX) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).ALPS Medical Breakthroughs ETF (SBIO).

What other stocks do shareholders of Protagonist Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).
When did Protagonist Therapeutics IPO?: Protagonist Therapeutics (PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.
Who are Protagonist Therapeutics' major shareholders?: Protagonist Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.06%) and Los Angeles Capital Management LLC (0.05%). Insiders that own company stock include Asif Ali, David Y Liu, Dinesh V Ph D Patel, Suneel Gupta and William D Waddill.
View institutional ownership trends.
How do I buy shares of Protagonist Therapeutics?: Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PTGX) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Protagonist Therapeutics (PTGX) Stock Price, News & Analysis

Protagonist Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Protagonist Therapeutics Stock (NASDAQ:PTGX)

PTGX Stock Price History

PTGX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PTGX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™